美常安干预肠易激综合征伴小肠细菌过度生长的研究

目的通过美常安干预肠易激综合征(IBS)伴小肠细菌过度生长(SIBO)患者,探讨IBS与SIBO之间的关系。方法选取40例IBS患者为IBS组,40例健康志愿者为对照组,两组患者治疗前均进行乳果糖氢呼气试验(LHBT)明确SIBO情况。IBS组中SIBO阳性者予美常安干预,观察其治疗前后的症状变化,疗程结束后复查LHBT。结果 IBS组患者SIBO发病率为55.0%,对照组为10.0%,两组患者SIBO发病率比较差异有统计学意义(P0.05);IBS组中SIBO阳性患者治疗后显效1例,有效12例,无效6例,脱落3例,有效率为68.0%,SIBO转阴率为57.9%。IBS组中SIBO阳性患者治疗前后腹胀程度、排便频率异常时间、排便时腹痛率及总积分比较差异有统计学意义(P0.05)。结论 IBS患者SIBO发病率远高于健康者,美常安能改善IBS伴SIBO患者部分症状及SIBO发病率,IBS的发生与SIBO之间存在一定关系,但对于IBS患者单纯补充益生菌制剂疗效并不理想,仍需结合其他手段进行干预。

Medilac-s intervention on irritable bowel syndrome with small intestinal bacterial overgrowth

Abstract: Objective To explore the relationship between irritable bowel syndrome (IBS) and small intestine bacterial overgrowth (SIBO) through Medilac-s intervention. Methods 40 patients with IBS were enrolled as the IBS group, with 40 healthy individuals as the controls. The two groups were given lactulose hydrogen breath test (LHBT) before treatment to learn the condition of SIBO. Medilac-s intervention was given to SIBO-positive patients in the IBS group; their symptoms before and after treatment were observed. LHBT was performed again after the treatment. Results The incidence rate of SIBO was 55.0% in the IBS group vs 10.0% in the control group (P<0.05). Medilac-s was markedly effective for 1 cases, effective for 12 cases, and invalid for 6 cases; there were 3 cases of drop-out. The efficiency rate was 68.0% and SIBO negative conversion rate was 57.9%. There were significant differences in the symptom scores of SIBO positive patients (P<0.05) before and after treatment. Conclusion The incidence rate of SIBO in IBS patients were much higher than that in healthy people. Medilac-s can improve some of the symptoms and reduce SIBO incidence. There is a certain relationship between SIBO and IBS. But for IBS patients, probiotics alone is not ideally effective and need to be combined with other means of intervention.